Inhibitors of glucose transporters (GLUTs)

US12060362B2 · kind B2 · utility

Assignees

• Lead Discovery Center GmbH · DE
• Max-Planck-Gesellschaft zur Föderung der Wissenschaften e.V. · US

Inventors

• Herbert Waldmann · Villingen, DE
• Gunther Zischinsky · Berlin, DE
• Peter Nussbaumer · Schwanenstadt, AT
• Slava Ziegler · Dortmund, DE
• Melanie Schwalfenberg · Cork, IE
• Javier de Ceballos Cerrajeria · Romanel-sur-Morges, CH
• Elena Sabrina Reckzeh · Dortmund, DE
• George Karageorgis · Essen, DE

Key dates

• Filing date: Sep 5, 2019
• Grant date: Aug 13, 2024
• Expiry date: Apr 12, 2041

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P37/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to 2,6-methanobenzo[g][1]oxacin-4-one compounds and their analog compounds and pharmaceutically acceptable salts thereof as selective inhibitor of glucose transporters 1 and 3 (GLUTs 1 and 3), to methods of preparing said compounds, and to the use thereof as pharmaceutically active agents, especially for the prophylaxis and/or treatment of metabolic diseases, immunological diseases, autoimmune diseases, inflammation, graft versus host disease, cancer, and metastasis thereof. Furthermore, the present invention is directed to pharmaceutical composition comprising at least one of 2,6-methanobenzo[g][1]oxacin-4-one compounds and their analog compounds.